Trial Profile
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizumab for metastatic colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms CCOG1202
- 10 Sep 2013 New trial record